Telitacicept for Autoimmune-related Lung Scarring
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new injection called telitacicept for people with lung scarring caused by autoimmune diseases like rheumatoid arthritis or lupus. It aims to see if the drug can slow down lung damage and help you breathe better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have one of these autoimmune diseases: rheumatoid arthritis, lupus, inflammatory myopathy, Sjogren's syndrome, systemic sclerosis, or mixed connective tissue disease
- A CT scan shows scarring or inflammation (interstitial lung disease) in at least 10% of your lungs
- Your breathing is stable enough that you can complete a lung function test (you don't need oxygen and can walk a short distance)
- You have been on a stable treatment plan for your lung and autoimmune disease before starting the trial
- You haven't used certain strong medications (like biologic drugs, chemotherapy, or anti-fibrotic drugs) in the past few weeks or months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This study tests a treatment plan for people who have rheumatoid arthritis and interstitial lung disease (scarring in the lungs). The goal is to find the best way to treat both conditions together and slow lung damage.
This trial tests telitacicept to improve lupus nephritis (inflammation of the kidneys caused by lupus). It targets people with active kidney disease confirmed by biopsy and compares outcomes while you receive standard steroid plus mycophenolate treatment.
Hear when a new CTD-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.